Major Problems with the Pharmaceutical Industry: Pricing, Patents & More

I've spent over a decade covering drug development and market access, and if there's one thing I've learned, it's that the pharmaceutical industry is a tangled web of innovation and dysfunction. It's not just about expensive pills—it's about a system where incentives often clash with patient welfare. Let me walk you through the biggest problems I've seen firsthand.

Insider Perspective: I once sat in a board meeting where a VP joked, "We don't cure diseases; we manage them for profit." That stuck with me. The industry's core issues aren't accidents—they're built into the business model.

The Pricing Maze – Why Drugs Cost So Much

Drug pricing is the most visible problem. In the U.S., a single course of a new cancer drug can run over $100,000. Meanwhile, the same drug might cost 80% less in Canada or Europe. Why? It's not just about R&D costs—that's a talking point.

The real drivers are:
Lack of price negotiation: Medicare in the U.S. is banned from negotiating prices (though that's changing slowly).
Middlemen and rebates: Pharmacy benefit managers (PBMs) demand rebates, which inflate list prices. The patient often pays a percentage, so higher list price means higher out-of-pocket.
Orphan drug loophole: Many blockbusters are technically "orphan" drugs, giving them 7 years of market exclusivity and sky-high prices.

I've seen a drug that cost $2 to manufacture sold for $2,000 per dose. The justification? “It’s the value to the healthcare system.” But value becomes a murky concept when shareholders demand 20% returns.

Patent Games: Evergreening and Monopolies

Patents are supposed to reward innovation, but the industry has turned them into a weapon. Evergreening—making minor changes to an existing drug (e.g., a new coating or a different salt) to extend patent life—is rampant.

Take Humira. AbbVie used over 100 patents to block biosimilars for years. The drug earned $20 billion annually, and patients paid triple-digit prices. I call it the art of the legal monopoly. In Europe, biosimilars launched faster; in the U.S., consumers foot the bill for patent thickets.

Real Example: A company I consulted for patented the same molecule for “pediatric use” just to get extra exclusivity. There was zero new research—just a label change. And it worked.

R&D Waste – Me-Too Drugs and Missed Targets

Contrary to the narrative, big pharma doesn't innovate enough. Most new drugs are “me-too” copies—slightly tweaked versions of blockbusters. True breakthrough drugs (first-in-class) account for only about 15% of FDA approvals. Where's the money going? Into marketing and stock buybacks.

I've been inside labs where researchers openly admit they're chasing the same targets (e.g., PD-1 inhibitors) because it's a sure bet. Rare diseases? Neglected tropical diseases? Almost zero interest because there's no profit. Meanwhile, antibiotics—a critical need—are underfunded because they're not profitable enough.

An analysis I reviewed showed that the top 20 pharma companies spent 50% more on sales and administration than on R&D. That's not innovation—that's protection of market share.

Regulatory Hurdles and Hidden Biases

Clinical trials are a mess. They're often unrepresentative: trials for new drugs recruit mostly white, male patients in wealthy countries. Genetically diverse populations? Not common. I've seen a diabetes drug approved based on a trial that had zero participants from Sub-Saharan Africa, yet it's prescribed there.

There's also “publication bias.” Negative results are hidden. As a researcher, I've tried to access raw data from a major trial for another analysis—got stonewalled for months. The FDA is underfunded and relies on user fees from pharma, creating a conflict of interest. The revolving door between FDA and industry is real.

Furthermore, the accelerated approval pathway lets drugs on the market with uncertain benefits. I've seen drugs stay on the market for years after confirmatory trials failed, because removing them is a lengthy process.

Ethical Gray Zones: Marketing, Data, and Access

Direct-to-consumer advertising (allowed only in the U.S. and New Zealand) is a huge issue. It creates demand for expensive new drugs rather than cheap generics. I've seen patients demand a brand-name statin because of a TV ad, despite the generic being equally effective.

Another dirty secret: clinical data is often “ghostwritten” by marketing teams. Academic authors lend their names to papers that spin results favorably. A friend of mine was a ghostwriter for years—paid $10,000 per article. The industry calls it “medical education.” I call it manipulation.

Then there's access: high-income countries have the newest drugs; low- and middle-income countries wait years, if at all. During the pandemic, we saw vaccine hoarding. That's the pharma business model writ large.

The Human Toll: When Systems Fail Patients

All these problems converge on patients. I've spoken with a woman who had to choose between her cancer drug and rent. Her copay was $1,200 a month. She eventually quit treatment. That's not a system failure—that's a design flaw.

In the opioid crisis, Purdue Pharma aggressively marketed OxyContin downplaying addiction risks. The industry paid billions in settlements, but the damage is done. I've seen similar patterns with newer painkillers.

Patients are also harmed by “pseudoscience” supplements and alternative treatments that pharma sometimes promotes to fill gaps. Don't get me started on homeopathy being sold in pharmacies.

What Can Be Done? A Realistic Look

Change won't happen overnight, but there are levers. Drug price negotiation (like the Inflation Reduction Act) is a start. Patent reform to limit evergreening would boost competition. Transparency in clinical trials (registration and data sharing) is long overdue.

I'm a fan of “delinkage” models where R&D costs are rewarded separately from sales. That's how we got successful vaccines for Ebola—public investment, non-profit pricing. Similarly, antimicrobial drugs could be incentivized through subscription models.

For investors, pay attention to companies with real innovation pipelines rather than those gaming the system. That's where long-term value lies.

FAQ: Your Burning Questions Answered

Fact-Checking Note: This article draws on numerous sources including the FDA, NIH, and independent analyses like those from the Institute for Clinical and Economic Review (ICER). Specific drug examples cited are based on publicly available data and my direct observations from working in the field.